Qube Research & Technologies LTD Cytom X Therapeutics, Inc. Transaction History
Qube Research & Technologies LTD
- $65.7 Billion
- Q3 2024
A detailed history of Qube Research & Technologies LTD transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 55,108 shares of CTMX stock, worth $58,965. This represents 0.0% of its overall portfolio holdings.
Number of Shares
55,108
Previous 54,608
0.92%
Holding current value
$58,965
Previous $66,000
1.52%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CTMX
# of Institutions
71Shares Held
50.7MCall Options Held
112KPut Options Held
8.3K-
Tang Capital Management LLC San Diego, CA7.81MShares$8.36 Million0.79% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$5.59 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.16MShares$5.52 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X04.81MShares$5.15 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA3.1MShares$3.32 Million0.01% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $70.6M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...